Sarepta Therapeutics Reports Q3 2026 Results with Improved Operating Income and Raised Revenue Guidance
Sarepta Therapeutics (SRPT) reported third-quarter 2026 revenue of $381.4 million, a 5% year-over-year decrease primarily due to lower ELEVIDYS sales volumes following its ambulatory-only label restriction. Despite the revenue dip, the company achieved a significant turnaround in profitability, reporting non-GAAP operating income of $22.9 million compared to a loss in the prior year period. The company raised its full-year 2026 revenue guidance to a range of $1.25 billion to $1.30 billion and demonstrated improved cost management through restructuring. While facing $62 million in take-or-pay manufacturing charges related to ELEVIDYS, Sarepta maintains a strong liquidity position with nearly $1 billion in cash and investments.
